Orange Book product · Generic (ANDA)
MESALAMINE
MESALAMINE
At a glance
May 06, 2022
Approved
Generic (ANDA)
Application
Not listed
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
May 06, 2022
4 yr 2 mo ago
Today
Pharmaceutical detail
Active ingredient
MESALAMINE
Strength
375MG
Dosage form
CAPSULE, EXTENDED RELEASE
Route
ORAL
TE code
Not listed
Application
ANDA 209970
Product number
001
Marketing status
DISCN
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of MESALAMINE
- 2013DELZICOLBrand (NDA)
NDA 204412 · ABBVIE
- 2008APRISOBrand (NDA)
NDA 022301 · SALIX
- 2008ASACOL HDBrand (NDA)
NDA 021830 · ABBVIE
- 2007LIALDABrand (NDA)
NDA 022000 · TAKEDA PHARMS USA
- 2004CANASABrand (NDA)
NDA 021252 · ABBVIE
- 1993PENTASABrand (NDA)
NDA 020049 · TAKEDA PHARMS USA
- 1992ASACOLBrand (NDA)
NDA 019651 · APIL
- 1990ROWASABrand (NDA)
NDA 019919 · MEDA PHARMS
- 1987ROWASABrand (NDA)
NDA 019618 · MYLAN SPECIALITY LP
- 2026MESALAMINEGeneric (ANDA)
ANDA 220016 · KLM LABS PVT
- 2026MESALAMINEGeneric (ANDA)
ANDA 219997 · DIFGEN PHARMS
- 2025MESALAMINEGeneric (ANDA)
ANDA 219864 · ANNORA PHARMA
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
